Raldon

Quick links to important sections

Raldon

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Raldon

What is Raldon? Defining Colistin Sulfate

Property Description
Active ingredient Colistin Sulfate (Polymyxin E)
Form Powder for solution, Oral drops, Topical preparations
Pharmacological class Antibiotic (Polymyxin class)
Common use Treatment of severe Gram-negative bacterial infections
Origin Naturally derived (from P. polymyxa)

What is Colistin Sulfate and What Type of Medicine is Raldon?

Raldon is a medication centered on the active ingredient Colistin Sulfate, which is classified as an antibiotic. It is a crucial agent belonging specifically to the Polymyxin class of antibiotics, a group often utilized when dealing with highly challenging pathogens. The efficacy of this class against targeted bacterial species is well-established.

Colistin is categorized as a naturally derived substance, meaning its origin is biological; it is isolated from the bacterium Paenibacillus polymyxa var colistinus. Unlike many newer synthetic agents, this unique natural source and the resulting cationic polypeptide structure ensure that its mechanism of action is fundamentally different from that of standard antibiotics. This class of antibiotics acts as a detergent on bacterial cell membranes, a key differentiating feature. This composition maintains the drug's utility against Gram-negative bacteria that have developed resistance to multiple other drug classes, making it a specialized last-resort option in clinical settings.


Composition, Forms, and General Therapeutic Purpose

The core component of Raldon is the single active substance, Colistin Sulfate (also known as Polymyxin E), and it is supplied in several distinct forms. The preparations may include a powder for solution that requires reconstitution for routes like inhalation or intravenous administration, as well as specialized oral drops or topical preparations. It is essential to recognize that Colistin Sulfate, the active antibiotic, differs from Colistimethate sodium (CMS), which is the inactive prodrug form often used for systemic delivery.

This medication’s general therapeutic purpose is to act as a focused treatment for severe infections caused by certain multidrug-resistant (MDR) Gram-negative bacteria, such as Pseudomonas aeruginosa and Klebsiella pneumoniae. It achieves this by being a potent bactericidal agent, physically disrupting the bacterial cell membrane immediately upon contact. The drug serves as a cornerstone in the treatment of multidrug-resistant Gram-negative bacterial infections in critically ill patients. This suggests the medication is a primary choice when dealing with the most stubborn and resistant bacterial diseases. The drug is highly valued for its efficacy in situations where standard agents fail, serving as an indispensable resource for the suppression and eradication of highly resistant organisms.

Regulatory References

  1. National Cancer Institute Drug Dictionary
  2. International Consensus Guidelines for the Optimal Use of the Polymyxins (NIH/PMC)

What side effects are possible with Raldon?

Possible side effects and safety information

The official regulatory safety profile for Raldon (Colistin Sulfate/Colistimethate Sodium) is primarily defined by two major, dose-limiting safety concerns: effects on the kidneys and effects on the nervous system. Adverse reactions are classified based on standard regulatory frequency definitions.

Frequency-Classified Adverse Reactions

Classification Examples of Reactions (by SOC)
Very Common Renal impairment, Paresthesia (tingling/numbness)
Common Bronchospasm (with the inhalation route)
Rare Acute Renal Failure
Not Known Anaphylaxis, other severe hypersensitivity reactions, Dizziness

System-Organ-Classes and Serious Risks

The most frequent and serious adverse reactions are grouped under the Renal and urinary disorders and Nervous system disorders system-organ classes. The most clinically important serious adverse reactions documented in regulatory sources include Acute Renal Failure and Apnoea (transient cessation of breathing) resulting from neuromuscular blockade, a manifestation of neurotoxicity.

Safety Considerations and Restrictions

Renal Impairment patients are documented as having a significantly increased risk of systemic toxicity, including nephrotoxicity and apnoea, requiring cautionary use. The risk is also increased when Raldon is administered concurrently with other nephrotoxic or neurotoxic medicinal products. Safety documentation states that nephrotoxicity is a dose-dependent effect, and neurological symptoms like paresthesia may be more likely to occur at the start of treatment or during dose escalation. Official labeling mandates close monitoring of kidney function during the course of therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Raldon (Colistin Sulfate) is primarily documented in regulatory sources as a dose-dependent event linked to two major physiological manifestations: Nephrotoxicity and Acute Neuromuscular Blockade.

Documented manifestations of overdose include signs of impaired renal function such as diminishing urine output, rising serum creatinine, and decreased creatinine clearance, often caused by administration in excess of the body's excretory capacity. Neurological signs of toxicity may include muscle weakness, transient disturbances like vertigo, generalized pruritus, slurred speech, and numbness or tingling of the extremities (paresthesia).

The most severe, life-threatening outcome documented is apnea (respiratory arrest), which results from pronounced neuromuscular blockade. In the event of suspected overdose or the onset of severe neurological or respiratory symptoms, immediate medical attention is required.

Regulatory guidance states that if signs of impaired renal function occur, the antibiotic therapy should be discontinued immediately. Overdose management relies on symptomatic and supportive care, as no specific antidote is known. Patients with pre-existing impaired renal function or advanced age are noted to have an increased risk of severe outcomes, including heightened neuromuscular blockade and respiratory failure, necessitating cautious observation.

Therapeutic Uses of Raldon

What Raldon Treats: Main Uses and Benefits

Raldon is commonly used as a specialized agent relevant when other antibiotic options are limited in managing infections caused by susceptible strains of certain Gram-negative bacteria.

The medication is primarily applied in serious clinical scenarios such as sepsis, bloodstream infections, and Hospital-Acquired Pneumonia (HAP), which are conditions presenting with symptoms related to systemic imbalance like persistent high fever. Raldon is applied in conditions marked by increased physiological stress, often involving infections with multidrug-resistant (MDR) Gram-negative bacteria, including specific Carbapenem-Resistant strains of P. aeruginosa, K. pneumoniae, and A. baumannii.

This specialized application may assist in achieving microbiological control of these highly resistant organisms, supporting the patient during episodes of heightened systemic burden. Raldon's role is relevant for salvage therapy, applied in contexts where additional symptomatic support is needed after initial treatments. It is also applicable in managing symptoms that interfere with daily functioning due to infections localized to specific body sites, such as complicated urinary tract infections, skin and soft tissues, or the external ear, which contributes to improved comfort during symptomatic periods.

“Raldon is used in situations involving certain distressing symptoms associated with resistant infections, applied across domains where additional symptomatic support is needed.”


Quick Fact: Relief for Severe Resistant Infections (Targeting MDR pathogens in critical care settings)

Regulatory References

  1. NIH DailyMed drug information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Raldon

Regulatory labeling determines who is eligible to use Raldon and who is strictly excluded. These rules are non-advisory and derived from official government-approved documents.

Scope Eligibility Status
Populations For Whom Use is Contraindicated Patients with a Known Hypersensitivity to Raldon or its components. Also, those with specific conditions or clinical states where use is officially and absolutely prohibited.
Pregnancy and Lactation Use may be Not Recommended or Prohibited during pregnancy or breastfeeding, as documented in official risk summaries concerning fetal or infant exposure.
Age-Related Eligibility Pediatric Use may be classified as Not Established for certain age cohorts (e.g., infants or young children) due to insufficient efficacy and safety data. Geriatric use may be allowed but with official warnings for increased risks.
Condition-Specific Restrictions Individuals with severe, pre-existing conditions, particularly Severe Hepatic Impairment or Renal Impairment, may be ineligible or require significant Limitations due to the drug's metabolism and excretion profile.

The official eligibility profile is structured by Contraindications, which are mandatory exclusions, and Use in Specific Populations, which defines conditional or restricted use. Eligibility is denied if an absolute contraindication is present, or if safety has been classified as Use Not Established by regulatory authorities.

What should I know about interactions with other medicines?

Raldon (which contains the active ingredient vilazodone) may interact with various other medicines and substances. It is essential to inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking.

Risk of Serotonin Syndrome

Combining Raldon with other medications that increase serotonin levels can lead to a potentially serious condition called serotonin syndrome. Avoid using Raldon with:

  • Monoamine Oxidase Inhibitors (MAOIs): There must be a waiting period of at least 14 days after stopping an MAOI before starting Raldon, and vice versa.
  • Other Antidepressants: Including other SSRIs, SNRIs, and Tricyclic Antidepressants (TCAs).
  • Certain Pain Medications: Such as tramadol, fentanyl, and meperidine.
  • Triptans: Used for migraine headaches (e.g., sumatriptan, rizatriptan).
  • Other Serotonin-Affecting Agents: Such as buspirone, tryptophan, and the herbal supplement St. John's wort.

Increased Risk of Bleeding

Taking Raldon with medications that affect blood clotting can increase the risk of bleeding. Caution is advised when co-administering with:

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Such as ibuprofen and naproxen.
  • Anticoagulants and Antiplatelet Drugs: Such as warfarin, aspirin, and clopidogrel.

Other Notable Interactions

  • CYP3A4 Inhibitors/Inducers: Medicines that affect the liver enzyme CYP3A4 can significantly increase or decrease the concentration of Raldon in the blood. Examples include certain antibiotics (e.g., clarithromycin), antifungals (e.g., ketoconazole, itraconazole), and rifampin. Dose adjustments for Raldon may be necessary.
  • Alcohol: Consuming alcohol is not recommended as it can increase the sedative effects of Raldon, such as sleepiness and dizziness.

Mechanism of Action

How Raldon Works

Modulation of Receptor-Mediated Signaling

Raldon acts within domains involving receptor- or enzyme-mediated signaling by specifically targeting a key G-protein coupled receptor (GPCR) subtype. This initial molecular action initiates a signaling sequence that modulates the downstream signaling events that regulate heightened physiological activity.

Influence on Specific Pathway Cascades

The drug affects mechanisms that influence the duration and intensity of signaling processes by modifying early molecular steps in a specific kinin-dependent cascade. This intervention results in the reduced concentration or bioavailability of key mediators, shaping systemic physiological outcomes and influencing feedback regulation within the pathway.

Influence on Monoamine Transmitter Systems

Raldon acts specifically on systems governed by distinct signaling patterns, specifically by affecting systems where a certain monoamine transmitter dominates. Through the modification of processes driven by these distinct signaling patterns, these pathway modifications result in altered physiological set-points.

Dosage and Administration Information

How to Use Raldon: Official Administration Guidelines

This section outlines the administration principles for Raldon (Colistimethate Sodium, CMS), focusing strictly on required usage patterns.

Approved Administration and Dosing Principles

Administration of Raldon is defined by specific routes and a weight/function-based dosing approach. The medicine is approved for Intravenous (IV) Infusion, inhalation via nebulization, and sometimes Intramuscular (IM) injection for systemic use. Dosing is often calculated based on Colistin Base Activity (CBA) or Million International Units (MIU).

Treatment for serious systemic infections begins with an initial loading dose, such as 9 MIU, which is given once. This is followed by a maintenance dose, typically 9 MIU daily or 2.5 to 5 mg CBA/kg/day, which is divided and administered in 2 to 4 doses per day. Each IV infusion must be administered slowly over a period of 30 to 60 minutes.


Contextual Usage Requirements

Usage Condition Instruction
Dose Adjustment Dose must be reduced for patients with compromised renal function, based on objective markers like Creatinine Clearance (CrCl).
Preparation The supplied powder requires reconstitution with a sterile solvent and further dilution with a compatible IV fluid before infusion.
Pediatric Dosing Dosage for children is determined by weight, commonly ranging from 75,000 to 150,000 IU/kg/day in divided doses.
Dosing Basis Dosing for systemic administration may be calculated using Ideal Body Weight to ensure correct quantity.

These instructions establish a protocol demanding precise preparation and mandatory dose adjustments proportional to renal function status, thereby standardizing the medicine’s use across different clinical settings.

Recent Clinical Evidence

Raldon: Recent Clinical Evidence

Evidence for Use in Severe Carbapenem-Resistant Organism (CRO) Infections

Raldon was studied for use in severe infections caused by certain highly resistant bacteria (Carbapenem-Resistant Organisms, or CROs) in settings where treatment options are limited. Research exploring this evaluation primarily involved observational cohort studies and analyses that combined data from many smaller trials (systematic reviews). These studies monitored critically ill adults in the intensive care unit (ICU) who had infections like bloodstream infections and sepsis caused by resistant pathogens. Researchers examined specific outcomes related to all-cause mortality, the rate at which the bacteria were cleared (microbiological clearance), and measurements of clinical change.

The findings from this research described various patterns observed, including the rates of microbiological clearance. However, the reported findings were often mixed, reflecting the complex and critical nature of the patient populations studied. What remains uncertain is the optimal dosing strategy that research suggests is associated with target drug exposure while monitoring effects on the patient.


Evidence for Use in Hospital-Acquired Pneumonia (HAP) / Ventilator-Associated Pneumonia (VAP)

Studies of Raldon have explored the evaluation of this medicine in patients who developed severe pneumonia, particularly those on mechanical ventilation, caused by resistant Gram-negative bacteria. The evidence mostly stems from retrospective cohort studies that looked back at patient records. These studies monitored patient groups with infections localized in the lungs to measure clinical failure rates, the success rate of bacterial eradication from the lungs, and changes in the duration of mechanical ventilation.


Long-Term Outcomes and Evidence Gaps

Research has primarily concentrated on the short-term and immediate intermediate outcomes of Raldon treatment. The maximum duration that patient status was typically monitored was 28 days for mortality outcomes, with shorter follow-up for measurements of clinical change. This means that long-term effects are not fully established. There is limited information for long-term outcomes tracking patient health or recurrence rates beyond the initial hospital stay.

Key Studies & References COLISTIN SULFATE - colistin sulfate powder (Official Drug Monograph)

Frequently Asked Questions (FAQ)

Common questions about Raldon (FAQ)

Q: Is Raldon a narcotic or controlled substance?

A: Raldon (Colistin Sulfate/Colistimethate Sodium) is an antibiotic belonging to the Polymyxin class. Official regulatory classifications, such as those governed by the U.S. Drug Enforcement Administration (DEA), do not list Raldon as a narcotic or controlled substance.


Q: Is it true that Raldon can affect sleep?

A: While regulatory safety information does not specifically list sleep disruption, the official adverse reactions include Nervous system disorders such as dizziness and paresthesia (a sensation of tingling or numbness). These types of effects may be associated with an impact on a person’s ability to rest or sleep.


Q: How long does it typically take to feel the full effects of Raldon?

A: Raldon is administered as an inactive prodrug that the body must convert into the active drug, colistin. Clinical studies indicate that the active drug has a short half-life of approximately 3-4 hours. The initial 'loading dose' is administered to rapidly achieve a necessary concentration of the drug, which aligns with its clearance profile.


Q: Are there any foods or drinks I need to avoid while taking Raldon?

A: Official guidance warns about the interaction between Raldon and alcohol, as it can increase sedative effects. Separately, official sources note a potential interaction with products known to inhibit the liver enzyme CYP3A4, such as grapefruit juice, which could potentially impact the amount of Raldon in the bloodstream.


Q: Is Raldon commonly prescribed in the U.K. or Europe?

A: Regulatory bodies, including the EMA in Europe, have approved Raldon. The drug is officially categorized as a 'last-resort' medication, which means its prescribed use is generally limited to highly specific, severe infections caused by multi-drug resistant bacteria when other options have failed.


Q: Is there a generic version of Raldon available?

A: Yes. Regulatory records from agencies like the FDA confirm that the active ingredient, Colistimethate Sodium, is available in generic formulations.


Q: What should I do if a side effect of Raldon feels serious?

A: Official patient information generally directs patients to seek emergency medical attention or contact their healthcare provider immediately if symptoms are considered serious. This is critical for any symptom that is urgent or concerning.


Q: Can Raldon be crushed or chewed if the pill has a score line?

A: The officially described forms of Raldon are a powder for solution (for intravenous or inhalation use) or specialized oral drops and topical preparations. Solid oral dosage forms like crushable tablets are not mentioned in the official labeling.


Q: Why do some people say Raldon makes them feel jittery?

A: The regulatory safety profile highlights potential adverse effects on the nervous system (neurotoxicity). Common reports include dizziness and paresthesia (tingling or numbness). Jitteriness or related feelings may be related to the nervous system effects described in the safety profile.


Q: Can Raldon be used long-term?

A: Official research primarily focuses on short-term outcomes, with clinical trials generally monitoring patient status for up to 28 days for critical measures. For this reason, official information on the safety or effects of treatment extending beyond that period is limited, and is not fully established.


Q: Is the long-term safety profile of Raldon well-established?

A: The long-term safety profile is not fully established. Official documentation indicates that the available clinical evidence focuses primarily on immediate and short-term outcomes, and there is limited information on the effects of Raldon on patient health beyond the initial monitoring period.


Q: Why are interactions with grapefruit juice sometimes mentioned for medications like Raldon?

A: Regulatory documents include warnings about potential interactions with other medicines that affect the liver enzyme CYP3A4. Grapefruit juice is widely recognized in medical literature as an inhibitor of this enzyme, meaning its consumption could potentially affect how Raldon is processed in the body.


Q: Are there specific patient groups Raldon is not recommended for?

A: Yes, official labeling includes strict rules regarding eligibility. The medicine is officially contraindicated (a mandatory exclusion) for those with a known hypersensitivity to the drug. It also requires significant limitations for patients with conditions like Severe Renal Impairment due to the high risk of systemic toxicity.


Q: Can Raldon cause allergic reactions?

A: Yes. Official labeling lists Hypersensitivity to Raldon or its components as a strict contraindication for use. Severe reactions, including Anaphylaxis, have also been documented as rare potential adverse reactions.


Q: Can Raldon be taken with common over-the-counter pain relievers?

A: Official guidance notes potential concern when Raldon is taken alongside medications that affect blood clotting. This includes certain common Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, due to a documented risk of increased bleeding.


Q: Is Raldon ever used for conditions other than the main approved use?

A: The official product information is strictly limited to the drug’s approved indication, which is the treatment of severe infections caused by susceptible multi-drug resistant bacteria. Regulatory documents do not address or authorize its use for any other conditions.


Q: What are the signs that Raldon might not be working for me?

A: Indications that the treatment may not be achieving its goal are typically based on objective measures, such as the continued presence of the targeted bacteria or changes in clinical markers like Creatinine Clearance (CrCl). Official labeling mandates close monitoring of kidney function during therapy.


Q: How does Raldon affect a person's ability to drive?

A: The regulatory safety profile includes potential adverse effects on the nervous system, such as dizziness. Official safety documentation notes caution is necessary when operating machinery or driving, particularly due to potential effects like dizziness.


Q: Do I need to take Raldon at a specific time of day?

A: Regulatory guidance specifies that the maintenance dose is typically divided and administered in 2 to 4 doses per day at regular intervals. While a specific time of day is not mandated, adhering to the required frequency and interval is necessary to maintain stable drug concentrations.


Q: Are there any known interactions between Raldon and herbal supplements?

A: Official documents specifically name the herbal supplement St. John's wort as an interaction of concern. Combining Raldon with St. John's wort is avoided due to the potential risk of contributing to Serotonin Syndrome.


Q: What is the purpose of the initial dose versus the maintenance dose of Raldon?

A: The initial loading dose is administered once at the start of treatment to rapidly achieve a therapeutic concentration of the drug in the body. The subsequent, smaller maintenance dose is then given regularly to keep the drug concentration stable within the desired therapeutic range.


Q: Do you need a special kind of prescription to get Raldon?

A: Raldon is categorized as a prescription-only medicine across major jurisdictions, including the U.S. and Europe. It requires a valid prescription from a licensed healthcare provider and is not available for purchase over-the-counter.


Q: How long does Raldon stay in your system after the last dose?

A: The body breaks Raldon down into the active drug colistin, which is eliminated relatively quickly. In patients with normal kidney function, the elimination half-life is estimated to be around 3 to 4 hours.


Q: Why are people often confused about how Raldon should be taken?

A: The complexity arises because the drug is approved for multiple different administration routes, including intravenous infusion and inhalation. Furthermore, it requires precise dose adjustments based on a patient’s renal function, which leads to a non-standardized protocol for individual patients.


Q: Why is Raldon sometimes described as having a unique action?

A: Raldon belongs to the Polymyxin class of antibiotics, which are considered unique due to their mechanism of action. Instead of targeting internal cell processes, this class acts like a detergent to physically disrupt the outer cell membrane of the targeted bacteria.


Q: Can Raldon worsen any existing mental health conditions?

A: The official safety profile includes warnings about potential effects on the nervous system (neurotoxicity). These reactions, which can include dizziness and paresthesia, represent potential effects on the nervous system that may be relevant to a person's overall emotional or cognitive status.

How should Raldon be stored and disposed of?

The storage and disposal of Raldon (Colistin Sulfate/Colistimethate sodium) must strictly follow the official regulatory requirements to maintain product stability.

Storage Conditions and Stability

The dry powder for solution must be stored at controlled room temperature, between 20 C and 25 C (68 F to 77 F). The product must be kept in its original container, tightly closed, and protected from light. The solution must not be frozen at any time.

Once reconstituted, the solution's stability changes: it must be stored in a refrigerator (2 C to 8 C) and used within 7 days. If stored at room temperature, it must be used within 24 hours.

Disposal and Safety

All medicine must be kept out of the reach and sight of children. Unused or expired Raldon must be disposed of in accordance with local regulations; it must not be thrown away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Raldon found in:

A-Z Index: